Tuesday, 10 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 10 March 2026
News

17 new drug labels under review

 Posted 10 March 2026 AM

The TGA will review new indications for 17 drugs, spanning a range of therapeutic areas including cardiovascular, oncology, immunology, neurology and ophthalmology.

Two of the 17 type C applications, accepted between November and January cover cardiovascular indications, with Eli Lilly’s GIP/GLP-1 receptor agonist Mounjaro looking to be used to lower the risk of cardiovascular problems, such as heart attack, stroke, or death from heart disease in adults who have type 2 diabetes and already have cardiovascular disease.

To see the whole article, please login

Popular

Who's been gifted a long weekend?
Global CEO quits for life in Australia
Best pharmas for women
Funding boosts local cancer trials
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home